MedPath

Tagged News

10x Genomics Partners with Singapore Institute to Launch AI-Driven Cancer Drug Discovery Study

AIDrug DiscoveryPrecision Medicine
  • 10x Genomics and A*STAR Genome Institute of Singapore announced the TISHUMAP project, an ambitious collaboration to analyze up to 2,500 clinical tissue samples using AI and spatial biology technology.
  • The study will focus on gastric, liver, and colorectal cancers, utilizing 10x Genomics' Xenium platform to visualize gene activity within individual cells in intact tissues.
  • The collaboration aims to accelerate drug target discovery and enable precision medicine by identifying novel biomarkers and therapeutic targets for cancer and inflammatory diseases.
  • Advanced AI will be combined with spatial omics data to detect critical patterns across large datasets, potentially leading to new diagnostics and personalized treatment plans.

OpenEvidence Raises $210 Million Series B to Expand AI-Powered Medical Research Platform for Physicians

AI
  • OpenEvidence, an AI-powered medical search engine for physicians, raised $210 million in Series B funding at a $3.5 billion valuation, co-led by Google Ventures and Kleiner Perkins.
  • The platform is used by over 40% of U.S. physicians daily and supports over 8.5 million clinical consultations per month, demonstrating over 2,000% year-over-year growth.
  • The company launched OpenEvidence DeepConsult, an AI agent that provides physicians with PhD-level medical research capabilities, analyzing hundreds of peer-reviewed studies in parallel.
  • Strategic partnerships with leading medical journals including JAMA and The New England Journal of Medicine enable instant access to evidence-based medical information for clinical decision-making.

MSBAI Secures $2M DoD Phase III Contract for GURU Generation 2 AI Platform

AI
  • MSBAI has been awarded a $2 million Phase III contract by the U.S. Department of Defense for GURU Generation 2, an AI-powered automation platform for engineering workflows.
  • The GURU platform reduces simulation failure rates from 88% to 2% and cuts setup times from hours or days to minutes for computational fluid dynamics simulations.
  • GURU Generation 2 will scale across key military supercomputers to support over 5,000 defense scientists and engineers in hypersonic vehicle development.
  • The contract elevates MSBAI to 'SBIR unicorn' status and positions the company for further DoD investments in AI-accelerated engineering innovation.

Tempus AI Receives FDA 510(k) Clearance for ECG-Low EF Software to Detect Heart Failure Risk

AI
  • Tempus AI received FDA 510(k) clearance for its Tempus ECG-Low EF software, which uses artificial intelligence to identify patients with low left ventricular ejection fraction from standard ECG recordings.
  • The software analyzes 12-lead ECG recordings to detect signs associated with LVEF ≤40% in patients aged 40 and older at risk of heart failure, including those with diabetes, hypertension, and other cardiovascular conditions.
  • This represents Tempus's second FDA-cleared ECG-AI device following Tempus ECG-AF, expanding the company's cardiovascular diagnostic capabilities for early detection of serious cardiac conditions.
  • The technology is designed as a screening tool that requires clinical interpretation alongside other diagnostic information and is not intended as a standalone diagnostic device.

bioAffinity Technologies Secures International Patents for CyPath Lung Cancer Diagnostic in China and Canada

AI
  • bioAffinity Technologies received patent approvals in China and Canada for its CyPath Lung diagnostic platform, which uses flow cytometry analysis of sputum to detect lung cancer.
  • The CyPath Lung test demonstrates 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small nodules less than 20 millimeters.
  • China represents a significant market opportunity with over 300 million smokers and 1.06 million new lung cancer cases diagnosed in 2022, while Canada sees approximately 31,000 new cases annually.
  • The patents protect the use of defined antibodies and porphyrin TCPP to label cell populations in sputum, strengthening the company's global intellectual property portfolio.

Elix and LINC Launch World's First Commercial AI Drug Discovery Platform Using Federated Learning from 16 Pharmaceutical Companies

AIDrug Discovery
  • Elix and LINC have commercialized the world's first AI drug discovery platform incorporating federated learning models trained on data from 16 pharmaceutical companies, addressing the critical data scarcity challenge in AI drug discovery.
  • The platform leverages over 1 million compounds and 10 million data points through the kMoL federated learning library, enabling collaborative AI model development while preserving confidential pharmaceutical data.
  • The initiative emerged from Japan's AMED DAIIA project and includes AI models for on/off-target prediction, ADMET prediction, and molecular generation, with several pharmaceutical companies already adopting the Elix Discovery™ platform.
  • The commercialization represents a significant milestone in pharmaceutical AI, positioning the platform to become the de-facto standard for AI drug discovery in Japan while contributing to enhanced drug development capabilities globally.

Biophytis Partners with Lynx Analytics to Accelerate AI-Driven Drug Discovery for Sarcopenia

AIDrug Discovery
  • Biophytis SA has announced a strategic partnership with Lynx Analytics to leverage artificial intelligence for accelerating small molecule drug discovery targeting sarcopenia, a condition with no FDA-approved treatments.
  • The collaboration will combine Biophytis' expertise in age-related disease biology with Lynx's advanced AI platforms to identify and optimize compounds for muscle preservation and regeneration.
  • The partnership aims to significantly reduce development time and costs while building a robust pipeline of drug candidates to restore muscle function for sarcopenia patients.

UAEU Researcher Secures Four Patents for Computational Drug Design and Medical Device Innovations

AI
  • Dr. Alya A. Arabi from United Arab Emirates University has been granted four patents spanning computational drug design and medical device development.
  • Two patents introduce novel methods for classifying and matching molecular conformers to enhance in-silico drug discovery processes while reducing laboratory experiments.
  • The third patent presents a breakthrough orthopedic device enabling patients with complete shoulder paralysis to regain full range of motion.
  • A fourth patent addresses male infertility from retrograde ejaculation and urinary incontinence through a dual-functionality biomedical device.

SimBioSys Receives Third FDA Clearance for AI-Powered Breast Cancer Surgery Platform TumorSight Viz

AI
  • SimBioSys secured its third FDA 510(k) clearance for TumorSight Viz 1.3, an AI-powered platform that converts standard breast MRI into 3D visualizations for surgical planning in breast cancer care.
  • The latest version introduces industry-leading AI-driven segmentation accuracy, faster case processing that produces results in minutes, and streamlined workflow integration with PACS connectivity.
  • Clinical validation demonstrates strong concordance with radiologist annotations and consistent performance across more than 1,600 retrospective cases from over nine institutions.
  • The platform addresses the critical need for precision in breast cancer surgery, where re-excision rates remain above 20 percent and significant variability exists in surgical decisions among experienced providers.

Clinical Trial System Faces Sustainability Crisis as Costs Soar and Workforce Shrinks

AI
  • The clinical trial workforce has declined dramatically, with investigators dropping from 128,303 to 116,948 globally and coordinators falling from 56,036 to 40,472 between 2017-2024.
  • Oncology trial costs have reached unsustainable levels, averaging $30 million for Phase 1 trials and nearly $60 million for Phase 3 studies, with total drug development costs hitting $2.3 billion.
  • Only 5-8% of eligible patients participate in clinical trials, while 60-70% of trial sites fail to meet enrollment targets, creating a bottleneck that threatens future drug development.
  • AI-driven platforms and decentralized trial models offer potential solutions to address recruitment inefficiencies and expand access to underserved rural communities.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.